Featured Items |view more
Immunotherapy – Targeted Drug Combination Improves Survival in Advanced Kidney Cancer
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent have longer survival than patients treated with the standard targeted drug.
Institute Research Shines at Society of Gynecologic Oncology Annual Meeting
Researchers in the Division of Gynecologic Oncology reported results from an array of clinical trials, gave an overview of trials currently under way, and presented promising findings from the lab.
High Concentrations of Immune Cells Within Tumors Associated with Longer Patient Survival
ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort ...
Clinical Trial Shows That Adding Bevacizumab to Targeted Drug and Chemotherapy Produces Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
Long-term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma
Tool for Identifying Appropriate Clinical Trials of Targeted Therapies Produces Hundreds of “Matches” at Dana-Farber
MatchMiner: An open-source AI precision medicine trial matching platform
Personal Organoids Could Help Individualize Cancer Treatment
Individualizing treatment using patient derived organoids, BH3 profiling and microfluidics: A proof of concept in a patient with low-grade serous ovarian carcinoma
Receive Dana-Farber's e-newsletter, Momentum, to learn of advances in cancer research and care, current clinical trials, and upcoming CME programs.
- American Society of Hematology (ASH) Annual Meeting
- San Antonio Breast Cancer Symposium
- Breast Cancer Treatment
- Research News Updates
- Faculty Updates
- Symposium Highlights 75 Years of Dana-Farber Science